Á. Salamon

发表

[The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis].

G. Blaskó, J. Hamvas, J. Tarján, 1999, Orvosi hetilap.

The real face of juvenile polyposis syndrome.

T. Molnár, A. Bajtai, Á. Salamon, 2012, Journal of gastrointestinal oncology.

[Vitamin D level in Hungarian patients with inflammatory bowel diseases].

Z. Tulassay, M. Tóth, P. Lakatos, 2013, Orvosi hetilap.

Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease.

F. Nagy, M. Papp, P. Lakatos, 2010, Journal of Crohn's & colitis.

[Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease].

T. Molnár, M. Papp, P. Lakatos, 2010, Orvosi hetilap.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

A family with two consecutive nonsense mutations in BMPR1A causing juvenile polyposis.

S. Chinnathambi, D. Calva, J. Bair, 2008, Cancer genetics and cytogenetics.

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

G. Veres, K. Farkas, F. Nagy, 2011, Alimentary pharmacology & therapeutics.

[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].

G. Veres, K. Farkas, F. Nagy, 2011, Orvosi Hetilap.

Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study

K. Farkas, F. Nagy, T. Molnár, 2019, Expert opinion on biological therapy.

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

K. Farkas, T. Molnár, M. Papp, 2016, Journal of Crohn's & colitis.

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Inflammatory bowel diseases.

Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

F. Nagy, T. Molnár, M. Papp, 2009, BMC gastroenterology.

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long‐term extension data from a Phase 3 study

J. Mansfield, Fraser Cummings, T. Molnár, 2016, Alimentary pharmacology & therapeutics.

Reversible protein-losing hypertrophic gastropathy: causal relationship with Helicobacter pylori infection, or simple coincidence?

Á. Salamon, L. Simon, I. Fehĕr, 2000, American Journal of Gastroenterology.

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.

Teck Kiang Tan, J. Mansfield, Fraser Cummings, 2021, The lancet. Gastroenterology & hepatology.

814 - Phase Iii Randomized Controlled Trial to Compare Biosimilar Infliximab (CT-P13) with Innovator Infliximab in Patients with Active Crohn's Disease: 1-Year Maintenance and Switching Results

S. Fishman, B. Ye, Kang-Moon Lee, 2018 .

DOP061 Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results.

S. Fishman, B. Ye, M. Scribano, 2017, Journal of Crohn's & Colitis.

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Expert opinion on drug safety.

Phase III Randomized, Double-Blind, Controlled Trial to Compare Biosimilar Infliximab (CT-P13) with Innovator Infliximab (INX) in Patients with Active Crohn's Disease: Early Efficacy and Safety Results

S. Fishman, B. Ye, Kang-Moon Lee, 2017 .

Final Results on Immunogenicity Profile and Predictors of ADA Development of Biosimilar Infliximab During the First 12 Months of the Therapy: Results from a Prospective Nationwide Cohort

K. Farkas, T. Molnár, M. Papp, 2017 .

P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort.

T. Molnár, M. Papp, P. Lakatos, 2017, Journal of Crohn's & colitis.

P331 Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort.

F. Nagy, T. Molnár, M. Papp, 2017, Journal of Crohn's & colitis.

F. Nagy, M. Papp, P. Lakatos, 2015 .

[Obstetrical and gynecological relevance of inflammatory bowel disease].

L. Harsányi, J. Wacha, J. Bajor, 2012, Orvosi hetilap.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Tu1140 Is It Necessary to Perform X-Ray Absorptiometry in Young IBD Patients to Predict the Risk of Fracture?

Z. Tulassay, P. Lakatos, L. Herszényi, 2013 .